Efprezimod alfa
Based on 1 Customer Validation
Efprezimod alfa (MK-7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome.
Nos produits utilisent uniquement pour la recherche. Nous ne vendons pas aux patients.
- Pureté : 99.25%
- CAS No.: 2574508-57-7
- Masse moléculaire:57.74 kDa
-
Stockage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Activité biologique
Description
Species Reactivity
Human
In Vitro
Fprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, and inhibiting the activation of antigen-presenting cells as well as subsequent inflammatory responses[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Conjugated
Unconjugated
Reconsititution
The product can be reconstituted/diluted with sterile PBS or saline.
Format
-
CD24 (CD24 molecule, CD24 antigen (small cell lung carcinoma cluster 4 antigen))-IGHG1 Fc (Fragment constant)
Chemical Information
-
CAS No. 2574508-57-7
-
Appearance Liquid
-
Masse moléculaire 57.74 kDa
-
Color Colorless to light yellow
-
SMILES
[Efprezimod alfa]
-
Synonyms
MK-7110; CD24 Fc
-
Livraison
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Stockage
Please store the product under the recommended conditions in the Certificate of Analysis.
Pureté et documentation
-
Fiche technique (271 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Inhibitory Antibodies User Guide (603 KB)
Références
[1]. Magenau J, et al. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 Jan 4;143(1):21-31. [Content Brief]
[2]. Du R, et al. Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?. Neuro Oncol. 2025;27(1):33-49. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)